Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.53 |
| ▸ | HTR2C | P28335 | 15/20 | 0.53 |
| ▸ | HTR2B | P41595 | 14/20 | 0.53 |
| ▸ | PNMT | P11086 | 4/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL2207496 | 0.90 | HTR2A (0.43) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL12433880 | 0.81 | HTR2A (0.48) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL2205606 | 0.80 | HTR2C (0.57) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL12433884 | 0.77 | HTR2A (0.53) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| Succinic Acid SCHEMBL2208430 | 0.76 | HTR6 (0.41) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| Succinic Acid SCHEMBL2210644 | 0.73 | HTR2C (0.46) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL2209263 | 0.71 | ESR1 (0.44) | — | |
| SCHEMBL10228373 | 0.71 | HTR2C (0.67) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL10227459 | 0.71 | HTR2A (0.67) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| Succinic Acid SCHEMBL2206581 | 0.71 | HTR2A (0.43) | HTR2AHTR2CHTR2BPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924578-B1 | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| US-7981882-B2 | e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981882-B2 | e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| WO-2007028132-A2 | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3B, HTR1A | HTR2A 5/4885HTR2C 1/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.